Cargando…

A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan

Japan has been running a nationwide antenatal human T-cell leukemia virus type-1 (HTLV-1) antibody screening program since 2010 for the prevention of HTLV-1 mother-to-child transmission. As part of the program, pregnant women are invited to take an HTLV-1 antibody screening test, usually within the...

Descripción completa

Detalles Bibliográficos
Autores principales: Itabashi, Kazuo, Miyazawa, Tokuo, Sekizawa, Akihiko, Tokita, Akifumi, Saito, Shigeru, Moriuchi, Hiroyuki, Nerome, Yasuhito, Uchimaru, Kaoru, Watanabe, Toshiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160230/
https://www.ncbi.nlm.nih.gov/pubmed/32328047
http://dx.doi.org/10.3389/fmicb.2020.00595
_version_ 1783522720522174464
author Itabashi, Kazuo
Miyazawa, Tokuo
Sekizawa, Akihiko
Tokita, Akifumi
Saito, Shigeru
Moriuchi, Hiroyuki
Nerome, Yasuhito
Uchimaru, Kaoru
Watanabe, Toshiki
author_facet Itabashi, Kazuo
Miyazawa, Tokuo
Sekizawa, Akihiko
Tokita, Akifumi
Saito, Shigeru
Moriuchi, Hiroyuki
Nerome, Yasuhito
Uchimaru, Kaoru
Watanabe, Toshiki
author_sort Itabashi, Kazuo
collection PubMed
description Japan has been running a nationwide antenatal human T-cell leukemia virus type-1 (HTLV-1) antibody screening program since 2010 for the prevention of HTLV-1 mother-to-child transmission. As part of the program, pregnant women are invited to take an HTLV-1 antibody screening test, usually within the first 30 weeks of gestation, during regular pregnancy checkups. Pregnant women tested positive on the antibody screening test undergo a confirmatory test, either western blotting or line immunoassay. In indeterminate case, polymerase chain reaction (PCR) is used as a final test to diagnose infection. Pregnant women tested positive on a confirmatory or PCR test are identified as HTLV-1 carriers. As breastfeeding is a predominant route of postnatal HTLV-1 mother-to-child transmission, exclusive formula feeding is widely used as a postnatal preventive measure. Although there is insufficient evidence that short-term breastfeeding during ≤3 months does not increase the risk of mother-to-child transmission compared to exclusive formula feeding, this feeding method is considered if the mother is eager to breastfeed her child. However, it is important that mothers and family members fully understand that there is an increase in the risk of mother-to-child transmission when breastfeeding would be prolonged. As there are only a few clinical studies on the protective effect of frozen-thawed breastmilk feeding on mother-to-child transmission of HTLV-1, there is little evidence to recommend this feeding method. Further study on the protective effects of these feeding methods are needed. It is assumed that the risk of anxiety or depression may increase in the mothers who selected exclusive formula feeding or short-term breastfeeding. Thus, an adequate support and counseling for these mothers should be provided. In addition to raising public awareness of HTLV-1 infection, epidemiological data from the nationwide program needs to be collected and analyzed. In most cases, infected children are asymptomatic, and it is necessary to clarify how these children should be followed medically.
format Online
Article
Text
id pubmed-7160230
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-71602302020-04-23 A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan Itabashi, Kazuo Miyazawa, Tokuo Sekizawa, Akihiko Tokita, Akifumi Saito, Shigeru Moriuchi, Hiroyuki Nerome, Yasuhito Uchimaru, Kaoru Watanabe, Toshiki Front Microbiol Microbiology Japan has been running a nationwide antenatal human T-cell leukemia virus type-1 (HTLV-1) antibody screening program since 2010 for the prevention of HTLV-1 mother-to-child transmission. As part of the program, pregnant women are invited to take an HTLV-1 antibody screening test, usually within the first 30 weeks of gestation, during regular pregnancy checkups. Pregnant women tested positive on the antibody screening test undergo a confirmatory test, either western blotting or line immunoassay. In indeterminate case, polymerase chain reaction (PCR) is used as a final test to diagnose infection. Pregnant women tested positive on a confirmatory or PCR test are identified as HTLV-1 carriers. As breastfeeding is a predominant route of postnatal HTLV-1 mother-to-child transmission, exclusive formula feeding is widely used as a postnatal preventive measure. Although there is insufficient evidence that short-term breastfeeding during ≤3 months does not increase the risk of mother-to-child transmission compared to exclusive formula feeding, this feeding method is considered if the mother is eager to breastfeed her child. However, it is important that mothers and family members fully understand that there is an increase in the risk of mother-to-child transmission when breastfeeding would be prolonged. As there are only a few clinical studies on the protective effect of frozen-thawed breastmilk feeding on mother-to-child transmission of HTLV-1, there is little evidence to recommend this feeding method. Further study on the protective effects of these feeding methods are needed. It is assumed that the risk of anxiety or depression may increase in the mothers who selected exclusive formula feeding or short-term breastfeeding. Thus, an adequate support and counseling for these mothers should be provided. In addition to raising public awareness of HTLV-1 infection, epidemiological data from the nationwide program needs to be collected and analyzed. In most cases, infected children are asymptomatic, and it is necessary to clarify how these children should be followed medically. Frontiers Media S.A. 2020-04-09 /pmc/articles/PMC7160230/ /pubmed/32328047 http://dx.doi.org/10.3389/fmicb.2020.00595 Text en Copyright © 2020 Itabashi, Miyazawa, Sekizawa, Tokita, Saito, Moriuchi, Nerome, Uchimaru and Watanabe. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Itabashi, Kazuo
Miyazawa, Tokuo
Sekizawa, Akihiko
Tokita, Akifumi
Saito, Shigeru
Moriuchi, Hiroyuki
Nerome, Yasuhito
Uchimaru, Kaoru
Watanabe, Toshiki
A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan
title A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan
title_full A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan
title_fullStr A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan
title_full_unstemmed A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan
title_short A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan
title_sort nationwide antenatal human t-cell leukemia virus type-1 antibody screening in japan
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160230/
https://www.ncbi.nlm.nih.gov/pubmed/32328047
http://dx.doi.org/10.3389/fmicb.2020.00595
work_keys_str_mv AT itabashikazuo anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT miyazawatokuo anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT sekizawaakihiko anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT tokitaakifumi anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT saitoshigeru anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT moriuchihiroyuki anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT neromeyasuhito anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT uchimarukaoru anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT watanabetoshiki anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT itabashikazuo nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT miyazawatokuo nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT sekizawaakihiko nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT tokitaakifumi nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT saitoshigeru nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT moriuchihiroyuki nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT neromeyasuhito nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT uchimarukaoru nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan
AT watanabetoshiki nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan